With the growing array of DMTs available for MS, DMT selection is still a challenge for the clinicians, particularly when initiating treatment for newly diagnosed MS

High-efficacy DMTs can significantly influence the long-term course of the disease; however, patient-related factors such as family planning, risk-benefit profiles, treatment adherence, and other personal preferences should be factored into the clinical decision making when selecting/switching DMTs

Navigate through a decision tree in a step-by-step matrix with supportive educational context and clinical commentary from expert faculty

Patient cases will sharpen decision-making skills to meet the treatment needs of diverse patients and discuss the variations of treatment options for women and men

Faculty

Riley Bove, MD, MSc

Associate Professor

Weill Institute for Neurosciences

University of California San Francisco

San Francisco, CA

Darin T. Okuda, MD, FAAN, FANA

Professor of Neurology

Director, Neuroinnovation Program

Director, Multiple Sclerosis & Neuroimmunology Imaging Program

Director, Radiologically Isolated Syndrome Consortium

Department of Neurology

UT Southwestern Medical Center at Dallas

Dallas, TX